Clinical Trials Logo

Clinical Trial Summary

A Phase 1 trial to assess the single-dose safety, tolerability, and pharmacokinetic (PK) of Methylene Blue Injection, USP 1 mg/kg in healthy adult voluneetrs.


Clinical Trial Description

This is an open-label, single-center, one-arm, safety, tolerability, and PK study in healthy male and female volunteers of Methylene Blue Injection, USP. Following an overnight fast, twelve healthy adult male and female volunteers will receive a single dose of study drug at a dose of 1 mg/kg solution per kg given intravenously over a period of 5 minutes followed by serial venous blood sampling at 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours postdose. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02478281
Study type Interventional
Source Luitpold Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date October 2012
Completion date March 2013

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02493283 - Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration Phase 1
Completed NCT03542760 - Acquired Methemoglobinemia Observational Registry
Active, not recruiting NCT00960050 - Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone Phase 1
Completed NCT00993694 - Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone N/A
Completed NCT01402869 - Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics N/A
Completed NCT01766999 - Methemoglobinemia After Liposuction - Diagnostic by Pulse Oximetry and Blood Gas Analysis.